Opioid Induced Constipation Clinical Trial
Official title:
A Single-arm, Open-label, Multicentre, Non-randomised, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy for the Reversal of Opioid-induced Constipation in Subjects Suffering From Malignant or Non-malignant Pain That Requires Around-the-clock Opioid Therapy
The main purpose of this study is to assess how effective and tolerable the country specific
clinical practice guidelines of SLTs are for UK, France and Sweden are.
The main rationale behind this study is that well controlled comparisons of the various
laxatives for the treatment of OIC are lacking. There is lack of evidence suggesting which
laxative or combination of laxatives is optimal for managing OIC.
The study comprises of nine study visits and the total duration of the study is up to 42-52
days Potential subjects, aged 18 years and over, with OIC will be screened for entry into
the study at Visit 1 Eligible subjects will attend a 7-day Screening Period (Visit 1). This
will be followed by a 28-day Treatment Period (visits 2 to 8:), made up of four clinic
visits scheduled 7 days apart (visits 5(day 7), 6(day 14), 7(day 21), 8(day 28): days 7 to
28) and two telephone visits (visits 3 and 4) which will take place during the first week of
the Treatment Period. There will be a 7-day Follow-up Period with a follow-up phone call to
conclude the study (Visit 9).
Study assessment/ evaluation include vital sign measurements, ECG, safety labs, pregnancy
test and physical examination assessments, AEs, Investigator and subject questionnaires and
subjects daily diaries.
Subjects will continue to take their prescribed pre-study opioid medication throughout the
study.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02813369 -
Naloxegol Health Outcome Post Authorisation Safety Study
|
||
Completed |
NCT01401985 -
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
|
Phase 2 | |
Completed |
NCT00984334 -
Naloxone SR Capsules in Patients With Opioid Induced Constipation
|
Phase 2 | |
Completed |
NCT01207427 -
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
|
Phase 2 | |
Completed |
NCT01459926 -
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation
|
Phase 2 | |
Terminated |
NCT01117051 -
Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation
|
Phase 3 | |
Completed |
NCT03060512 -
To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
|
Phase 4 | |
Completed |
NCT01109511 -
A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy
|
Phase 4 | |
Active, not recruiting |
NCT02813356 -
Naloxegol US PMR CV Safety.
|
||
Completed |
NCT01812733 -
Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives
|
N/A | |
Completed |
NCT01623609 -
Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol
|
Phase 1 | |
Completed |
NCT02813148 -
Naloxegol Drug Utilization Post Authorisation Safety Study
|
||
Completed |
NCT01443403 -
A Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy
|
Phase 2 | |
Completed |
NCT03638440 -
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.
|